PS10 aptomycin ClH/c22-6-7-29-8-9-30-10-11-31-12-13-32-16-3-1-2-14-18(16)21(28)24(20(14)27)15-4-5-17(25)23-19(15)26

ClH/c22-6-7-29-8-9-30-10-11-31-12-13-32-16-3-1-2-14-18(16)21(28)24(20(14)27)15-4-5-17(25)23-19(15)26

ML 145 acts as a competitive antagonist for a number of agonists at human GPR35 and has an IC50 value against EC80 concentrations of various GPR35 agonists in the region of 20 nM

CAS Number: 29479-00-3

Synta Pharmaceuticals Corp is developing apilimod for the potential treatment of Crohn's disease (CD) and other autoimmune diseases

PS10 aptomycin ClH/c22-6-7-29-8-9-30-10-11-31-12-13-32-16-3-1-2-14-18(16)21(28)24(20(14)27)15-4-5-17(25)23-19(15)26PS10 is a novel, potent and ATP competitive pan PDK inhibitor, inhibits all PDK isoforms with IC50 of 0. 8 M, 0. 76 M, 2. 1 M and 21. 3 M for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 M). PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy. PDK: pyruvate